UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 19, 2007
SCHERING—PLOUGH CORPORATION
(Exact Name of Registrant as Specified in its Charter)
| |
|
|
|
|
New Jersey
(State or Other Jurisdiction of
Incorporation)
|
|
1-6571
(Commission File Number)
|
|
22-1918501
(IRS Employer
Identification Number) |
2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (908) 298-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
ITEM 2.01 COMPLETION OF ACQUISITION OF ASSETS.
On
November 19, 2007, Schering-Plough Corporation closed the acquisition of
Organon BioSciences N.V. from Akzo Nobel N.V. for approximately €11 billion in cash. Organon
BioSciences is comprised primarily of Organon, a human health business, and Intervet, an animal
health business. It also includes Nobilon, a human vaccine development unit, and Diosynth, a
third-party manufacturing unit of Organon.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
99.1 Press release dated November 19, 2007 titled “Schering-Plough Completes Acquisition of Organon
BioSciences”